Last reviewed · How we verify
NCT05735977: Nephrogreen
Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared
NA trial testing Indocyanine Green (ICG) in Wilms Tumor in 12 participants. Completed in 6 January 2025.
6 January 2025
Quick facts
| Lead sponsor | Birmingham Women's and Children's NHS Foundation Trust |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 12 |
| Start date | 1 February 2023 |
| Primary completion | 6 January 2025 |
| Estimated completion | 6 January 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Indocyanine Green (ICG) — full drug profile →
Conditions studied
- Wilms Tumor — all drugs for Wilms Tumor →
- Renal Cancer — all drugs for Renal Cancer →
Sponsor
Birmingham Women's and Children's NHS Foundation Trust
Who can join
Adults 1 Day to 15, any sex, with Wilms Tumor or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Indocyanine Green (ICG) is a dye which fluoresces under near-infrared (NIR) light. It has been used for several applications in adult surgery. The CI is pioneering its use in children's kidney cancer surgery for lymph node identification and removal. This study concentrates on its use for procedures where only the part of the kidney containing tumour is removed. It is known that kidney tumours in both adults and children do not take up ICG at all. This absence of uptake can be used to define the border between normal and abnormal renal tissue giving a real-time picture of the area of tumour. This then delivers surgeons an intra-operative roadmap for removing only the cancerous part of the kidney. At present the international society of paediatric oncology - renal tumour study group (SIOP-RTSG) protocol, which is followed in the UK, advises consideration of partial nephrectomy for children with bilateral renal tumours and in children with unilateral tumours who have a renal tumour predisposition syndrome. There is ongoing debate about partial nephrectomy in unilateral renal tumour surgery in children who do not have a predisposition syndrome. This study aims to provide the evidence that paediatric renal tumours do not take up ICG at a naked-eye level and confirm this at a cell level. ICG will be infused into kidneys containing tumour once they have been removed from the patient, The kidney and tumour will be observed under NIR light to show where the areas of fluorescence are. Then, a pathologist will prepare the specimen in theatre, in the same way they would do in the lab. The specimen would be bivalved and reviewed under NIR. Microscopy specimens of the border between normal and abnormal tissue would then be reviewed with an NIR capable microscope. The standard histopathological assessment would then take place.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05735977
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Indocyanine Green (ICG)
Trials testing the same drug.
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT04258566 — Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies · NA · terminated
- NCT04511026 — Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer · Phase 2 · terminated
- NCT02949726 — Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development · Phase 1 · completed
- NCT02710240 — Indocyanine Green for Central Nervous System Tumors · Phase 1, PHASE2 · completed
Other recruiting trials for Wilms Tumor
Currently open trials in the same condition.
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
- NCT06198296 — Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells · Phase 1 · recruiting
- NCT04715191 — Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tu · Phase 1 · recruiting
- NCT05985161 — A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors · Phase 2 · recruiting
- NCT04897321 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) · Phase 1 · recruiting
Other Birmingham Women's and Children's NHS Foundation Trust trials
Trials by the same sponsor.
- NCT05971563 — Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers · NA · completed
- NCT05702294 — Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries . · NA · completed
- NCT04906551 — Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility · unknown
- NCT04854018 — Indo-cyanine Green (ICG) in Paediatric Oncology MIS · Phase 4 · completed
- NCT04751500 — The HYsteroscopic Miscarriage MaNagement Trial: A Pilot RCT Investigating a Novel Management Pathway for RPOC · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05735977 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Birmingham Women's and Children's NHS Foundation Trust
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05735977.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing